The effect of sodium butyrate on histone modification. Sealy L, Chalkley R (1978) Cell 14: 115-21 Epigenetic (re)programming of caste-specific behavior in the ant Camponotus floridanus. Simola DF, Graham RJ, Brady CM, Enzmann BL, Desplan C, Ray A, Zwiebel LJ, Bonasio R, Reinberg D, Liebig J, Berger SL (2016) Science 351: aac6633 Histone deacetylase inhibition accelerates the early events of stem cell differentiation: transcriptomic and epigenetic analysis. Karantzali E, Schulz H, Hummel O, Hubner N, Hatzopoulos A, Kretsovali A (2008) Genome Biol 9: R65 A role for transcriptional repression of p21CIP1 by c-Myc in overcoming transforming growth factor beta -induced cell-cycle arrest. Claassen GF, Hann SR (2000) Proc Natl Acad Sci U S A 97: 9498-503 Pan-histone deacetylase inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonists. Mandawat A, Fiskus W, Buckley KM, Robbins K, Rao R, Balusu R, Navenot JM, Wang ZX, Ustun C, Chong DG, Atadja P, Fujii N, Peiper SC, Bhalla K (2010) Blood 116: 5306-15 Histone deacetylase inhibitor enhances recovery after AKI. Cianciolo Cosentino C, Skrypnyk NI, Brilli LL, Chiba T, Novitskaya T, Woods C, West J, Korotchenko VN, McDermott L, Day BW, Davidson AJ, Harris RC, de Caestecker MP, Hukriede NA (2013) J Am Soc Nephrol 24: 943-53 Drug-induced activation of dopamine D(1) receptor signaling and inhibition of class I/II histone deacetylase induce chromatin remodeling in reward circuitry and modulate cocaine-related behaviors. Schroeder FA, Penta KL, Matevossian A, Jones SR, Konradi C, Tapper AR, Akbarian S (2008) Neuropsychopharmacology 33: 2981-92 Myc Induces miRNA-Mediated Apoptosis in Response to HDAC Inhibition in Hematologic Malignancies. Adams CM, Hiebert SW, Eischen CM (2016) Cancer Res 76: 736-48 Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Witta SE, Gemmill RM, Hirsch FR, Coldren CD, Hedman K, Ravdel L, Helfrich B, Dziadziuszko R, Chan DC, Sugita M, Chan Z, Baron A, Franklin W, Drabkin HA, Girard L, Gazdar AF, Minna JD, Bunn PA (2006) Cancer Res 66: 944-50 Histone deacetylase 3 controls a transcriptional network required for B cell maturation. Stengel KR, Bhaskara S, Wang J, Liu Q, Ellis JD, Sampathi S, Hiebert SW (2019) Nucleic Acids Res 47: 10612-10627 The coactivator role of histone deacetylase 3 in IL-1-signaling involves deacetylation of p65 NF-κB. Ziesché E, Kettner-Buhrow D, Weber A, Wittwer T, Jurida L, Soelch J, Müller H, Newel D, Kronich P, Schneider H, Dittrich-Breiholz O, Bhaskara S, Hiebert SW, Hottiger MO, Li H, Burstein E, Schmitz ML, Kracht M (2013) Nucleic Acids Res 41: 90-109 Coordinated changes of histone modifications and HDAC mobilization regulate the induction of MHC class II genes by Trichostatin A. Gialitakis M, Kretsovali A, Spilianakis C, Kravariti L, Mages J, Hoffmann R, Hatzopoulos AK, Papamatheakis J (2006) Nucleic Acids Res 34: 765-72 Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia. Odenike OM, Alkan S, Sher D, Godwin JE, Huo D, Brandt SJ, Green M, Xie J, Zhang Y, Vesole DH, Stiff P, Wright J, Larson RA, Stock W (2008) Clin Cancer Res 14: 7095-101 HDAC inhibitors regulate claudin-1 expression in colon cancer cells through modulation of mRNA stability. Krishnan M, Singh AB, Smith JJ, Sharma A, Chen X, Eschrich S, Yeatman TJ, Beauchamp RD, Dhawan P (2010) Oncogene 29: 305-12 Histone deacetylase inhibitors induce the degradation of the t(8;21) fusion oncoprotein. Yang G, Thompson MA, Brandt SJ, Hiebert SW (2007) Oncogene 26: 91-101 Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells. Ha K, Fiskus W, Choi DS, Bhaskara S, Cerchietti L, Devaraj SG, Shah B, Sharma S, Chang JC, Melnick AM, Hiebert S, Bhalla KN (2014) Oncotarget 5: 5637-50 Trichostatin-A modulates claudin-1 mRNA stability through the modulation of Hu antigen R and tristetraprolin in colon cancer cells. Sharma A, Bhat AA, Krishnan M, Singh AB, Dhawan P (2013) Carcinogenesis 34: 2610-21 Transforming growth factor beta mimetics: discovery of 7-[4-(4-cyanophenyl)phenoxy]-heptanohydroxamic acid, a biaryl hydroxamate inhibitor of histone deacetylase. Glaser KB, Li J, Aakre ME, Morgan DW, Sheppard G, Stewart KD, Pollock J, Lee P, O'Connor CZ, Anderson SN, Mussatto DJ, Wegner CW, Moses HL (2002) Mol Cancer Ther 1: 759-68 Smoking induces epithelial-to-mesenchymal transition in non-small cell lung cancer through HDAC-mediated downregulation of E-cadherin. Nagathihalli NS, Massion PP, Gonzalez AL, Lu P, Datta PK (2012) Mol Cancer Ther 11: 2362-72 T-bet dependent removal of Sin3A-histone deacetylase complexes at the Ifng locus drives Th1 differentiation. Chang S, Collins PL, Aune TM (2008) J Immunol 181: 8372-81 ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain. Amann JM, Nip J, Strom DK, Lutterbach B, Harada H, Lenny N, Downing JR, Meyers S, Hiebert SW (2001) Mol Cell Biol 21: 6470-83 Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer. Konstantinopoulos PA, Wilson AJ, Saskowski J, Wass E, Khabele D (2014) Gynecol Oncol 133: 599-606 Role of HDAC3 on p53 expression and apoptosis in T cells of patients with multiple sclerosis. Zhang F, Shi Y, Wang L, Sriram S (2011) PLoS One 6: e16795 Inhibition of histone deacetylase 3 causes replication stress in cutaneous T cell lymphoma. Wells CE, Bhaskara S, Stengel KR, Zhao Y, Sirbu B, Chagot B, Cortez D, Khabele D, Chazin WJ, Cooper A, Jacques V, Rusche J, Eischen CM, McGirt LY, Hiebert SW (2013) PLoS One 8: e68915 Evaluation of long-term transgene expression in piggyBac-modified human T lymphocytes. Nakazawa Y, Saha S, Galvan DL, Huye L, Rollins L, Rooney CM, Wilson MH (2013) J Immunother 36: 3-10 Modification of histones immediately following synthesis. Sealy L, Chalkley R (1979) Arch Biochem Biophys 197: 78-82 The DNA damage mark pH2AX differentiates the cytotoxic effects of small molecule HDAC inhibitors in ovarian cancer cells. Wilson AJ, Holson E, Wagner F, Zhang YL, Fass DM, Haggarty SJ, Bhaskara S, Hiebert SW, Schreiber SL, Khabele D (2011) Cancer Biol Ther 12: 484-93 The effects of the histone deacetylase inhibitor romidepsin (FK228) are enhanced by aspirin (ASA) in COX-1 positive ovarian cancer cells through augmentation of p21. Son DS, Wilson AJ, Parl AK, Khabele D (2010) Cancer Biol Ther 9: 928-35 HDAC inhibitors in kidney development and disease. Brilli LL, Swanhart LM, de Caestecker MP, Hukriede NA (2013) Pediatr Nephrol 28: 1909-21
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.